Study of Atiprimod Treatment for Patients With Advanced Cancer

Summary

Primary Objectives: The primary objectives of this study are to identify the maximum tolerated dose (MTD) and to evaluate the safety of atiprimod when given in doses starting at 60 mg/day and ranging to 360 mg/day, or the MTD, whichever is lower, in patients with advanced cancer. Secondary Objectives: The secondary objectives of this study are to measure the pharmacokinetics of atiprimod and to evaluate the efficacy of atiprimod treatment in patients with advanced cancer, and to compare the pharmacokinetics of atiprimod tablets and capsules at the starting dose, with the intent of switching to capsules for the dose escalation if the capsules pose no safety issues.

Timeline

Start

2005-03

Primary completion

2012-02

Completion

2012-02

Outcome

Outcome not reported

Stopped: “Sponsor Withdrew”

Drugs

Indications